Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2018-002132-25 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A randomized, double-blind, placebo controlled, multicenter Phase 3 trial to evaluate the efficacy, safety, tolerability, quality of life and impact on normal daily activities of ARGX-113 in patients with gMG.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ARGX-113 | Experimental |
| |
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ARGX-113 | Biological | Intravenous administration of ARGX-113 |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of MG-ADL Responders During Cycle 1 (C1); Analyzed in the AChR-Ab Seropositive Population | The MG-ADL is an 8-item patient-reported scale to assess MG symptoms and their effects on daily activities. The scale comprises 2 items on daily life activities and 6 items on symptoms. The MG-ADL total score range is 0-24, with higher scores indicative of greater disease severity. A patient was considered an MG-ADL responder during C1 if there was a reduction of ≥2 points on the MG-ADL total score (compared to baseline of C1 [C1B]) for ≥4 consecutive weeks with the first reduction occurring no later than 1 week after the last infusion of IMP in C1. | Baseline up to Day 63 (end of TC1) |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Quantitative Myasthenia Gravis (QMG) Responders During C1; Analyzed in the AChR-Ab Seropositive Population | The QMG scale quantifies disease severity based on impairments of body functions and structures as defined by the International Classification of Disability and Health. The QMG scale consists of 13 items that measure endurance or fatigability, and accounts for fluctuations in disease state. The QMG total score range is 0-39, with higher scores indicative of greater disease severity. A patient was considered a QMG responder during C1 if there was a reduction of ≥3-points on the QMG total score (compared to C1B) for ≥4 consecutive weeks with the first reduction occurring no later than 1 week after the last infusion of IMP in C1. |
Not provided
Inclusion Criteria:
Other, more specific inclusion criteria are defined in the protocol
Exclusion Criteria:
Pregnant and lactating women, and those intending to become pregnant during the trial or within 90 days after the last dosing.
Male patients who are sexually active and do not intend to use effective methods of contraception during the trial or within 90 days after the last dosing or male patients who plan to donate sperm during the trial or within 90 days after the last dosing.
MGFA Class I and V patients.
Patients with worsening muscle weakness secondary to concurrent infections or medications.
Patients with known seropositivity or who test positive for an active viral infection at Screening with:
Other, more specific exclusion criteria are further defined in the protocol.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Antonio Guglietta, MD | argenx | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Investigator Site 29 | Phoenix | Arizona | 85018 | United States | ||
| Investigator Site 66 |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42234197 | Derived | Howard JF Jr, Sacca F, Hoffmann S, Attarian S, De Bleecker JL, Beauchamp J, Brauer E, Kerstens R, Vissing J, Meisel A; ADAPT Study Group. Clinical effectiveness of efgartigimod in a broad population of patients with generalized myasthenia gravis: subgroup analyses from a randomized, double-blind, placebo-controlled, phase 3 trial (ADAPT). J Neurol. 2026 Jun 3;273(6):363. doi: 10.1007/s00415-026-13877-z. | |
| 41517964 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Total study duration was up to 28 weeks, including a 2-week screening period, an initial 8-week treatment cycle (TC) and intertreatment cycle (ITC) of variable length depending on the patient. Patients had to be on a stable dose of SoC and not have received immunoglobulins by IV, subcutaneous or intramuscular route, or plasma exchange, < 1 month prior to screening. The study included both AChR-Ab seropositive and seronegative patients; AChR-Ab detection in serum was performed during screening.
Study was conducted in generalized myasthenia gravis (gMG) patients at 56 sites worldwide. Patients were randomized 1:1 within each stratum (Japanese/non-Japanese, acetylcholine receptor-antibody [AChR-Ab] status and standard of care [SoC; ie, concomitant gMG treatment]) to receive ARGX-113 intravenous (IV) 10 milligrams/kilogram (mg/kg) or placebo, in addition to SoC. Patients completing the study were eligible to roll over into a follow-up study ARGX-113-1705.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | ARGX-113 | Patients received ARGX-113 IV 10 mg/kg administered as a 1-hour infusion every 7 days for 4 infusions (Days 1, 8, 15, and 22) in each cycle. Each 8-week TC comprised a 3-week treatment period and a 5-week follow-up period. At the end of each TC, patients entered the ITC period consisting of visits every 2 weeks. At each ITC visit, retreatment criteria were evaluated to determine if the patient was eligible to enter the next cycle for retreatment, based on clinical response as measured by the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Jul 11, 2019 | Sep 22, 2021 |
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Biological | Intravenous administration of placebo |
|
| Baseline up to Day 63 (end of TC1) |
| Percentage of MG-ADL Responders During C1; Analyzed in the Overall Population | The percentage of MG-ADL responders during C1 in the overall population is reported for this secondary end point; percentage of MG-ADL responders during C1 in the AChR-Ab seropositive population is reported previously as a primary end point. | Baseline up to Day 63 (end of TC1) |
| Percentage of Time That Patients Had a Clinically Meaningful Improvement (CMI) in MG-ADL Total Score up to and Including Day 126; Analyzed in the AChR-Ab Seropositive Population | An MG-ADL CMI was defined as a reduction of ≥2 points on the total MG-ADL score compared to study entry baseline (SEB). | Baseline up to Day 126 |
| Time From Week 4 to Qualify for Retreatment; Analyzed in the AChR-Ab Seropositive Population | Time to qualify for retreatment was defined as time from the Week 4 assessment until the first visit with a <2-point reduction compared to SEB in the MG-ADL total score and MG-ADL total score ≥5 points with >50% of the total score attributable to nonocular symptoms. | Week 4 up to Day 182 (end of study [EoS]) |
| Percentage of Early MG-ADL Responders During C1; Analyzed in the AChR-Ab Seropositive Population | A patient was considered an early MG-ADL responder during C1 if there was a reduction of ≥2 points on the MG-ADL total score (compared to C1B) for ≥4 consecutive weeks with the first reduction occurring no later than Week 2 (ie, after 1 or maximum 2 infusions of IMP in C1). | Baseline up to Day 63 (end of TC1) |
| Carlsbad |
| California |
| 92011 |
| United States |
| Investigator Site 5 | Los Angeles | California | 90033 | United States |
| Investigator Site 49 | Los Angeles | California | 90095 | United States |
| Investigator Site 18 | Orange | California | 92868 | United States |
| Investigator Site 40 | Palo Alto | California | 94304 | United States |
| Investigator Site 59 | San Francisco | California | 94115 | United States |
| Investigator Site 58 | Aurora | Colorado | 80045 | United States |
| Investigator Site 34 | Jacksonville | Florida | 32209 | United States |
| Investigator Site 4 | Tampa | Florida | 33612 | United States |
| Investigator Site 30 | Springfield | Illinois | 62702 | United States |
| Investigator Site 25 | Iowa City | Iowa | 52242 | United States |
| Investigator Site 21 | Kansas City | Kansas | 66160 | United States |
| Investigator Site 27 | Boston | Massachusetts | 02115 | United States |
| Investigator Site 48 | Detroit | Michigan | 48201 | United States |
| Investigator Site 53 | Buffalo | New York | 14202 | United States |
| Investigator Site 3 | Chapel Hill | North Carolina | 27599 | United States |
| Investigator Site 20 | Cleveland | Ohio | 44195 | United States |
| Investigator Site 9 | Portland | Oregon | 97239 | United States |
| Investigator Site 17 | Charleston | South Carolina | 29425 | United States |
| Investigator Site | Cordova | Tennessee | 38018 | United States |
| Investigator Site 44 | Houston | Texas | 77030 | United States |
| Investigator Site 6 | San Antonio | Texas | 78229 | United States |
| Investigator Site 2 | Charlottesville | Virginia | 22908 | United States |
| Investigator Site 16 | Seattle | Washington | 98195 | United States |
| Investigator Site 11 | Edegem | 2650 | Belgium |
| Investigator Site 8 | Ghent | 9000 | Belgium |
| Investigator Site 38 | Edmonton | Alberta | T6G 2G3 | Canada |
| Investigator Site 24 | Toronto | Ontario | M5G 2C4 | Canada |
| Investigator Site 22 | Montreal | Quebec | H3A 2B4 | Canada |
| Investigator Site 32 | Brno | 62500 | Czechia |
| Investigator Site 35 | Ostrava-Poruba | 70852 | Czechia |
| Investigator Site 51 | Prague | 128 00 | Czechia |
| Investigator Site 36 | Aarhus | 8200 | Denmark |
| Investigator Site 15 | Copenhagen | 2100 | Denmark |
| Investigator Site 13 | Bordeaux | 33076 | France |
| Investigator Site 52 | Marseille | 13385 | France |
| Investigator Site 46 | Tbilisi | 0112 | Georgia |
| Investigator Site 45 | Tbilisi | 0114 | Georgia |
| Investigator Site 47 | Tbilisi | 0114 | Georgia |
| Investigator Site 33 | Berlin | 10117 | Germany |
| Investigator Site 55 | Budapest | 1204 | Hungary |
| Investigator Site 54 | Szeged | 6725 | Hungary |
| Investigator Site 10 | Milan | 20133 | Italy |
| Investigator Site 12 | Naples | 80131 | Italy |
| Investigator Site 42 | Chiba | Chiba | 260-8677 | Japan |
| Investigator Site 26 | Sapporo | Hokkaido | 0608543 | Japan |
| Investigator Site 19 | Hanamaki | Iwate | 025-0075 | Japan |
| Investigator Site 43 | Sendai | Miyagi | 983-8520 | Japan |
| Investigator Site 28 | Ōsaka-sayama | Osaka | 5898511 | Japan |
| Investigator Site 50 | Suita | Osaka | 565-0871 | Japan |
| Investigator Site 31 | Meguro City | Tokyo | 1538515 | Japan |
| Investigator Site 41 | Minato-Ku | Tokyo | 108-8329 | Japan |
| Investigator Site 39 | Shinjuku-Ku | Tokyo | 160-0023 | Japan |
| Investigator Site 37 | Leiden | 2333 ZA | Netherlands |
| Investigator Site 7 | Gdansk | 80-952 | Poland |
| Investigator Site 57 | Katowice | 40-123 | Poland |
| Investigator Site 14 | Krakow | 31-505 | Poland |
| Investigator Site 23 | Warsaw | 02-097 | Poland |
| Investigator Site 64 | Krasnoyarsk | 660037 | Russia |
| Investigator Site 62 | Nizhny Novgorod | 603126 | Russia |
| Investigator Site 65 | Novosibirsk | 630087 | Russia |
| Investigator Site 60 | Samara | 443095 | Russia |
| Investigator Site 61 | Belgrade | 11000 | Serbia |
| Investigator Site 63 | Edgbaston | B15 2TH | United Kingdom |
| Investigator Site 56 | Liverpool | L9 7LJ | United Kingdom |
| Derived |
| Hoffmann S, Zhao S, Callewaert F, Schoppe S, Rozsa C, Spillane J. Post Hoc, Sex-Specific Subgroup Analysis of Efgartigimod in Patients With Generalized Myasthenia Gravis From the ADAPT Trial: A Sex and Gender Equity in Research (SAGER) Guidelines Approach. Muscle Nerve. 2026 Apr;73(4):566-574. doi: 10.1002/mus.70135. Epub 2026 Jan 10. |
| 39068745 | Derived | Janssen MF, Dewilde S, Wolfe GI, Muppidi S, Phillips G. Psychometric properties of MG-ADL items and MG-ADL score: An assessment of distributional characteristics, validity and factor structure in two large datasets. J Neurol Sci. 2024 Aug 15;463:123135. doi: 10.1016/j.jns.2024.123135. Epub 2024 Jul 22. |
| 34146511 | Derived | Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. |
| FG001 | Placebo | Patients received matching placebo administered as a 1-hour infusion every 7 days for 4 infusions (Days 1, 8, 15, and 22) in each cycle. Each 8-week TC comprised a 3-week treatment period and a 5-week follow-up period. At the end of each TC, patients entered the ITC period consisting of visits every 2 weeks. At each ITC visit, retreatment criteria were evaluated to determine if the patient was eligible to enter the next cycle for retreatment, based on clinical response as measured by the MG-ADL scale. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
All patients in the randomized population who received at least a partial dose of investigational medicinal product (IMP) were included in the baseline analysis.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | ARGX-113 | Patients received ARGX-113 IV 10 mg/kg administered as a 1-hour infusion every 7 days for 4 infusions (Days 1, 8, 15, and 22) in each cycle. |
| BG001 | Placebo | Patients received matching placebo administered as a 1-hour infusion every 7 days for 4 infusions (Days 1, 8, 15, and 22) in each cycle. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Age, Customized | Count of Participants | Participants |
| ||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Race/Ethnicity, Customized | Count of Participants | Participants |
| ||||||||||||||||
| Concomitant gMG treatment | Count of Participants | Participants |
| ||||||||||||||||
| AChR-Ab status | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of MG-ADL Responders During Cycle 1 (C1); Analyzed in the AChR-Ab Seropositive Population | The MG-ADL is an 8-item patient-reported scale to assess MG symptoms and their effects on daily activities. The scale comprises 2 items on daily life activities and 6 items on symptoms. The MG-ADL total score range is 0-24, with higher scores indicative of greater disease severity. A patient was considered an MG-ADL responder during C1 if there was a reduction of ≥2 points on the MG-ADL total score (compared to baseline of C1 [C1B]) for ≥4 consecutive weeks with the first reduction occurring no later than 1 week after the last infusion of IMP in C1. | Analysis was performed in the AChR-Ab seropositive population using the modified intention-to-treat (mITT) analysis set which included all randomized patients with a value for the MG-ADL total score at baseline and at least 1 postbaseline timepoint. | Posted | Number | percentage of patients | Baseline up to Day 63 (end of TC1) |
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Quantitative Myasthenia Gravis (QMG) Responders During C1; Analyzed in the AChR-Ab Seropositive Population | The QMG scale quantifies disease severity based on impairments of body functions and structures as defined by the International Classification of Disability and Health. The QMG scale consists of 13 items that measure endurance or fatigability, and accounts for fluctuations in disease state. The QMG total score range is 0-39, with higher scores indicative of greater disease severity. A patient was considered a QMG responder during C1 if there was a reduction of ≥3-points on the QMG total score (compared to C1B) for ≥4 consecutive weeks with the first reduction occurring no later than 1 week after the last infusion of IMP in C1. | Analysis was performed in the AChR-Ab seropositive population using the mITT analysis set which included all randomized patients with a value for the MG-ADL total score at baseline and at least 1 postbaseline timepoint. | Posted | Number | percentage of patients | Baseline up to Day 63 (end of TC1) |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of MG-ADL Responders During C1; Analyzed in the Overall Population | The percentage of MG-ADL responders during C1 in the overall population is reported for this secondary end point; percentage of MG-ADL responders during C1 in the AChR-Ab seropositive population is reported previously as a primary end point. | Analysis was performed in the overall population (including both AChR-Ab seropositive and seronegative patients) using the mITT analysis set which included all randomized patients with a value for the MG-ADL total score at baseline and at least 1 postbaseline timepoint. | Posted | Number | percentage of patients | Baseline up to Day 63 (end of TC1) |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Time That Patients Had a Clinically Meaningful Improvement (CMI) in MG-ADL Total Score up to and Including Day 126; Analyzed in the AChR-Ab Seropositive Population | An MG-ADL CMI was defined as a reduction of ≥2 points on the total MG-ADL score compared to study entry baseline (SEB). | Analysis was performed in the AChR-Ab seropositive population using the mITT analysis set which included all randomized patients with a value for the MG-ADL total score at baseline and at least 1 postbaseline timepoint. | Posted | Least Squares Mean | Standard Error | percentage of time | Baseline up to Day 126 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Time From Week 4 to Qualify for Retreatment; Analyzed in the AChR-Ab Seropositive Population | Time to qualify for retreatment was defined as time from the Week 4 assessment until the first visit with a <2-point reduction compared to SEB in the MG-ADL total score and MG-ADL total score ≥5 points with >50% of the total score attributable to nonocular symptoms. | Analysis was performed in the AChR-Ab seropositive population using the mITT analysis set which included all randomized patients with a value for the MG-ADL total score at baseline and at least 1 postbaseline timepoint. | Posted | Median | 95% Confidence Interval | days | Week 4 up to Day 182 (end of study [EoS]) |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Early MG-ADL Responders During C1; Analyzed in the AChR-Ab Seropositive Population | A patient was considered an early MG-ADL responder during C1 if there was a reduction of ≥2 points on the MG-ADL total score (compared to C1B) for ≥4 consecutive weeks with the first reduction occurring no later than Week 2 (ie, after 1 or maximum 2 infusions of IMP in C1). | Analysis was performed in the AChR-Ab seropositive population using the mITT analysis set which included all randomized patients with a value for the MG-ADL total score at baseline and at least 1 postbaseline timepoint. | Posted | Number | percentage of patients | Baseline up to Day 63 (end of TC1) |
|
|
Treatment-emergent adverse events were monitored from first administration of IMP on Day 1 until the EoS (up to a maximum of approximately 182 days).
The safety analysis set included patients in the randomized population who received at least a partial dose of IMP.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | ARGX-113 | Patients received ARGX-113 IV 10 mg/kg administered as a 1-hour infusion every 7 days for 4 infusions (Days 1, 8, 15, and 22) in each cycle. | 0 | 84 | 4 | 84 | 49 | 84 |
| EG001 | Placebo | Patients received matching placebo administered as a 1-hour infusion every 7 days for 4 infusions (Days 1, 8, 15, and 22) in each cycle. | 0 | 83 | 7 | 83 | 48 | 83 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Thrombocytosis | Blood and lymphatic system disorders | MedDRA 23.0 | Systematic Assessment |
| |
| Atrial fibrillation | Cardiac disorders | MedDRA 23.0 | Systematic Assessment |
| |
| Myocardial ischaemia | Cardiac disorders | MedDRA 23.0 | Systematic Assessment |
| |
| Therapeutic product ineffective | General disorders | MedDRA 23.0 | Systematic Assessment |
| |
| Upper respiratory tract infection | Infections and infestations | MedDRA 23.0 | Systematic Assessment |
| |
| Procedural pain | Injury, poisoning and procedural complications | MedDRA 23.0 | Systematic Assessment |
| |
| Spinal compression fracture | Injury, poisoning and procedural complications | MedDRA 23.0 | Systematic Assessment |
| |
| Spinal ligament ossification | Musculoskeletal and connective tissue disorders | MedDRA 23.0 | Systematic Assessment |
| |
| Rectal adenocarcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 23.0 | Systematic Assessment |
| |
| Myasthenia gravis | Nervous system disorders | MedDRA 23.0 | Systematic Assessment |
| |
| Myasthenia gravis crisis | Nervous system disorders | MedDRA 23.0 | Systematic Assessment |
| |
| Depression | Psychiatric disorders | MedDRA 23.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Diarrhoea | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment |
| |
| Bronchitis | Infections and infestations | MedDRA 23.0 | Systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA 23.0 | Systematic Assessment |
| |
| Myalgia | Musculoskeletal and connective tissue disorders | MedDRA 23.0 | Systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA 23.0 | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA 23.0 | Systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment |
| |
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment |
| |
| Hypertension | Vascular disorders | MedDRA 23.0 | Systematic Assessment |
| |
| Upper respiratory tract infection | Infections and infestations | MedDRA 23.0 | Systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA 23.0 | Systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Regulatory Manager | argenx BVBA | +32 93103400 | regulatory@argenx.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | May 8, 2020 | Sep 22, 2021 | SAP_001.pdf |
| ID | Term |
|---|---|
| D009157 | Myasthenia Gravis |
| ID | Term |
|---|---|
| D020361 | Paraneoplastic Syndromes, Nervous System |
| D009423 | Nervous System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D010257 | Paraneoplastic Syndromes |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D019636 | Neurodegenerative Diseases |
| D020511 | Neuromuscular Junction Diseases |
| D009468 | Neuromuscular Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000718373 | efgartigimod alfa |
Not provided
Not provided
Not provided
| >= 65 years |
|
| Male |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Hispanic or Latino |
|
| Not Hispanic or Latino |
|
| Not Reported |
|
| No NSIDs |
|
| Negative |
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
|
|
|
|
|
|
|